ABBV Stock Recent News

ABBV LATEST HEADLINES

ABBV Stock News Image - fool.com

AstraZeneca and AbbVie outperformed the benchmark S&P 500 index over the past three-year, five-year, and 10-year periods. AbbVie offers a relatively high yield due to declining sales of its former lead drug Humira.

fool.com 2024 Sep 19
ABBV Stock News Image - fool.com

AbbVie's dividend growth has slowed, but new drugs are offsetting Humira's decline. The company's debt levels and payout ratio are high, but its shares screen as undervalued.

fool.com 2024 Sep 16
ABBV Stock News Image - fool.com

AbbVie has proved it can adapt to a fast-changing environment. Eli Lilly has a sustainable culture of growth.

fool.com 2024 Sep 14
ABBV Stock News Image - fool.com

AbbVie is a Dividend King that's proven it can successfully navigate patent cliffs. Brookfield Infrastructure offers attractive distributions and has a solid long-term growth strategy.

fool.com 2024 Sep 14
ABBV Stock News Image - forbes.com

Given its better valuation, we believe that Pfizer stock (NYSE: PFE) is currently a better pick than its industry peer – AbbVie stock . PFE stock trades at a much lower multiple of 11x forward, versus 20x for ABBV, and we think this gap in valuation will narrow in favor of Pfizer in the coming years.

forbes.com 2024 Sep 13
ABBV Stock News Image - fool.com

AbbVie is a superbly managed organization. The company's leaders expertly positioned it for Humira's loss of patent protection.

fool.com 2024 Sep 13
ABBV Stock News Image - zacks.com

AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

zacks.com 2024 Sep 12
ABBV Stock News Image - prnewswire.com

BOTOX® Cosmetic is the first neurotoxin approved in China for the treatment of masseter muscle prominence (MMP), the largest global market for MMP. Approval supported by well-established safety profile and robust clinical trials demonstrating BOTOX® Cosmetic is effective in reducing the prominence of the masseter muscle.

prnewswire.com 2024 Sep 11
ABBV Stock News Image - reuters.com

UnitedHealth Group said on Tuesday it will remove AbbVie's blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and recommend less expensive biosimilar versions of the medicine instead.

reuters.com 2024 Sep 10
ABBV Stock News Image - seekingalpha.com

Investing in dividend stocks allows you to earn dividend income, the best passive income stream. In August, we (my wife and I) received a dividend income total of $1,415.47. 2023 was up 24%. Eight months down in 2024 and the S&P 500 is still up 14%, despite the recent sell-offs. Unemployment is starting to tick up recently.

seekingalpha.com 2024 Sep 10
10 of 50